Rani Therapeutics Locks $1.09 B Licensing Deal with Japan’s Chugai Pharma
Biotech company Rani Therapeutics has signed a licensing agreement with Japan’s Chugai Pharmaceutical, worth up to $1.09 billion, to develop and market an oral version of a Chugai experimental antibody. Under the deal, Rani will receive an upfront $10 million, plus up to $75 million for development milestones and $100 million in sales milestones. Chugai…